Insulin resistance is an impaired insulin-mediated condition of glucose metabolism control, which is closely related with blood sugar, fat and energy metabolism and nervous regulation. It can result in inflammation, oxidative stress, endothelium damage, and neuronal apoptosis which brings about atherosclerosis. In addition, it can cause hypoperfusion causing neuron damage and apoptosis, which eventually leads to ischemic stroke and cognitive dysfunction. Recently, pharmacological findings that improving insulin resistance can reduce the risk of cardiovascular and cerebrovascular events, have become a growing field in the medical academy. Sodium-dependent glucose transporters-2 inhibitor Empagliflozin, which increases the insulin sensitivity in the brain by regulating hypothalamus response to insulin, is expected to become a new therapeutic approach to prevent or delay ischemic stroke. The newly-listed insulin sensitizer can simultaneously regulate the metabolism of blood glucose and blood lipids , improve the metabolic syndrome, and has a promising application in the prevention and treatment of stroke.